Table 5.
Summary of related meta-analysis for a first-line treatment of mCRC
| Meta-analysis | Included studies | Treatment | ORR | mPFS (month) | mOS (month) | SRR | Grade3/4 toxicity |
|---|---|---|---|---|---|---|---|
| Cremolini C [32] |
CHARTA OLIVIA STEAM TRIBE TRIBE2 |
bev+3-CT vs bev+2CTa |
64.5 vs 53.6% OR 1.57, P<0.001 |
12.2 vs 9,9 HR:0.74, P<0.001 |
28.9 vs 24.5 HR:0.81, P<0.001 |
16.4 vs 11.8% OR 1.48, P=0.007 |
Neutropenia 45.8 vs 21.5%; P<0.001 FN 6.3 vs 3.7%; P=0.019 Diarrhea 17.8 vs 8.4%; P<0.001 |
| C Bokemeyer [33] |
CRYSTAL OPUS |
Cet+2CT vs 2CT |
60.7 vs 40.9% OR 2.27, P <0.0001 |
10.9 vs 7.7 HR 0.64, P<0.0001 |
24.8 vs 21.1 HR 0.84, P =0.0048 |
NA | NA |
| F Pietrantonio [34] |
Valentino TRIBE TRIBE2 STEAM CHARTA. |
pan+3CT vs bev+3CT |
73 vs 77% OR 0.79, P =0.4 |
11.4 vs 13.3 HR 0.83, P =0.11 |
30.3 vs 33.1 HR 0.8, P =0.14 |
22 vs 18% P =0.51 |
Neutropenia 26 vs 48%; P =0.001 Diarrhea 14 vs 6%; P =0.82 Febrile stomatitis 8 vs 6%; P =0.67 |
| G Tomasello [35] | 11 studies | Bev+3CT |
69% (95%CI, 65–72%) |
12.4 (95%CI,10-14.3) |
30.2 (95%CI,26.5-33.7) |
36.6% (95%CI,24.6%-50.5%) |
NA |
aAll KRAS and BRAF wild type; ORR Objective response rate, SRR Secondary resection rate, mPFS Median progression-free survival, mOS Median overall survival, 2CT Doublet chemotherapy, 3CT Triplet chemotherapy, FN Febrile neutropenia